Magnitude Biosciences awarded grant to accelerate the identification of compounds that could slow ageing or treat age-related diseases

Photo: The Magnitude Biosciences Team

May 2023, Sedgefield, United Kingdom

Magnitude Biosciences Limited, a specialist provider of C. elegans research services to the longevity, nutraceuticals, and pharmaceutical industries based in the North East of England, has been awarded a Future Economy Investor Partnerships grant of nearly £250,000 by Innovate UK. 

The grant will be matched by an investment from the North East (ERDF) Innovation Fund Limited Partnership, supported by the European Regional Development Fund and managed by Northstar Ventures Limited. The North East (ERDF) Innovation Fund Limited Partnership is currently an investor in Magnitude Biosciences.

Magnitude Biosciences uses C. elegans, a nematode worm to identify compounds that could slow ageing or prevent age-related diseases. C. elegans has physiological similarities to humans and has been used by scientists investigating the mechanism of ageing for over 40 years. It has a very short lifespan so compounds can be assessed in just 7 days. 

Magnitude Biosciences has already developed its own novel imaging technology to monitor the effects of compounds on C. elegans. This grant will enable further automation to be introduced to increase the number of compounds that can be screened. This will dramatically increase the chances that customers will find potentially effective compounds and ensure that Magnitude Biosciences remains competitive.

See what the media says about our success:

The Northern Echo
Business Live
Insider Media

To find out how Magnitude Biosciences can support your research contact us via info@magnitudebiosciences.com 

Press Contact:

Jessica Evans jess@magnitudebiosciences.com

Related News

Magnitude Biosciences: Revolutionising Research
Contract research organisation Magnitude Biosciences is projecting significant growth as it looks to...Read More
Life Sciences consortium celebrate collective multi-million Biomedical Catalyst 2023 Innovate UK grant
Press Release: 24th July 2023 Photo:  From left to right: Prof Carrie Ambler, (LightOx) Dr Sam Whit...Read More
Magnitude Biosciences awarded grant to accelerate the identification of compounds that could slow ageing or treat age-related diseases
Photo: The Magnitude Biosciences Team May 2023, Sedgefield, United Kingdom Magnitude Biosciences Lim...Read More
AB Biotek works with Magnitude Biosciences to accelerate probiotic development
Magnitude Biosciences partnered with AB Biotek Human Nutrition & Health (ABB HNH), the global le...Read More
Pharmaceutical company Lundbeck in collaboration with Magnitude Biosciences on innovative new platform to test interventions for neurodegenerative disease
Lundbeck collaborates with Magnitude on innovate platform to test neurodegenerative disease interven...Read More
Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services
Magnitude Biosciences Limited, a specialist provider of C. elegans research services to the longevit...Read More
Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth
North East UK Biotech Magnitude Biosciences announces new CEO, Fozia Saleem, to accelerate the growt...Read More
SMER28 Extends Healthspan – Revealing a New Target for Ageing Therapeutics
Biotech entrepreneur Ethan Perlstein works with Magnitude Biosciences to reveal a new target for age...Read More
Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing
The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing res...Read More
Frontiers in Aging: Applying C. elegans to industrial drug discovery
Just published in Frontiers in Aging: Applying C. elegans to industrial drug discovery...Read More
Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms
The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims ...Read More
Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand
Durham, UK - July 29, 2021 Magnitude Biosciences, the world’s leading commercial lab services prov...Read More
Magnitude Biosciences recognised in Developed in Durham as local success story
Magnitude Biosciences has been recognised by Developed in Durham....Read More
The worm angle on the taurine story: a route to the clinic by understanding mechanism
Dr Manish Chamoli in the lab of Gordon Lithgow at the Buck Institute (Right) David Weinkove, 15 June...Read More
Magnitude Biosciences secures its second round of funding to support its pre-clinical research services
Magnitude Biosciences secures its second round of funding to support its pre-clinical research servi...Read More
Magnitude Biosciences announces new hires to support continued growth
Durham, UK - March 2021 Magnitude Biosciences, a spin-out from Durham University and the leading con...Read More
Magnitude Biosciences secures UK government Future Fund to expand its workforce.
Durham, UK - August 2020 Research into new medicines is needed more than ever, but research labs acr...Read More
Magnitude Biosciences' new COVID-19 compatible laboratory is fully operational and we are ready to support your research
Magnitude Biosciences moves its unique COVID-19 compatibletechnology to a new lab at NETPark in Sedg...Read More

CONTACT US

Get in touch today to find out how we can support you
to accelerate your research